跳至主要内容
临床试验/NCT03200743
NCT03200743Unknown不适用

Relationship Between Catestatin and Pregnant Hypertensive Disorders

Yuchen Pan1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2017年5月14日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
400
试验地点
1
主要终点
plasma level of Catestatin

研究概览

简要总结

Catestatin is a kind of protein involved with cardiovascular disease. Accumulated evidence shows that Catestatin may be a predictor of primary hypertension, but whether it plays the same role in pregnant hypertensive disorders needs to be determined. By measuring the plasma level of Catestatin, main biochemical marks and UCG in healthy pregnancy and pregnancy with hypertension, the research may contribute to this problem.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

性别
Female
接受健康志愿者
是

入选标准

  • •Healthy pregnancy women
  • •Pregnancy women with hypertension
  • •Despite the pregnant gestational age , systolic blood pressure ≥140 mm Hg OR a diastolic blood pressure of ≥90 mm Hg measured three times more than 24 hours apart
  • •Pregnant gestational age > 20 weeks, systolic blood pressure ≥140 mm Hg OR a diastolic blood pressure of ≥90 mm Hg measured twice more than 4 hours apart

排除标准

  • •Lack of blood sample at the specified enrollment period
  • •Women who refuse the study
  • •Other illness which needs medications interfering with blood pressure (eg: Asthma requiring systemic steroids)
  • •Known coronary artery disease or heart failure
  • •Serious medical illness (eg: renal insufficiency, congestive heart disease, chronic respiratory insufficiency, uncontrolled infection).
  • •multiple endocrine neoplasia or Cushing's syndrome or mixed tumours or pheochromocytoma or medullary thyroid carcinoma.
  • •previous history of malignant tumour, with the exception of carcinoma in situ of the uterine cervix or non-melanoma skin cancer
  • •renal insufficiency

结局指标

主要结局

plasma level of Catestatin

时间窗: once at the specified enrollment period

plasma level of Catestatin with the unit "mmol/l"

次要结局

  • blood pressure(the specified enrollment period,42 days and 2 months after the pregnancy)

研究者

发起方
Yuchen Pan
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Yuchen Pan

Peking University Third Hospital

Peking University Third Hospital

研究点 (1)

Loading locations...

相似试验